anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The present invention relates to a polynucleotide encoding a specific novel sorting nexin, SNX-B8/30 and is also related to a polypeptide encoded by said polynucleotides. The invention also relates to specific medical, pharmaceutical and scientific uses of said new member of a herein described sorting nexin (SNX) subgroup consisting of SNX-9, SNX- 18 and the herein described SNX-B8/30. Also provided are specific screening methods for agonists or antagonists influencing the function and/or expression of the SNX-B 8/30 and/or the further members of the herein identified subfamily of sorting nexins. Accordingly, the present invention also relates to novel pharmaceutical compositions. These pharmaceutical compositions may, inter alia, be employed in the treatment of diseases/disorders related to (pathological) APP metabolism and/or the insulin metabolism, like Alzheimer&#39;s disease or diabetes. Also provided are non-human transgenic animals comprising a modified and/or altered SNX-B8/30 or expressing a heterologous SNX-B8/30.
A method for treating a human patient includes screening for Crohn&#39;s disease by simultaneously contacting a human serum sample with an antigen composition comprising a 35 kD protein expressed by a recombinant p35 clone specific to sera from Johne&#39;s disease and a 36 kD protein expressed by a recombinant p36 clone specific to sera from Crohn&#39;s disease. A bound antibody-antigen complex to the antigen composition is detected, the bound antibody-antigen complex detecting a presence of  Mycobacterium avium  ss.  paratuberculosis  (MAP). If the screening results are positive, the patient is administered a regimen of an antibiotic effective in and sufficient for eradicating a presence of MAP. Preferably a probiotic and specific carbohydrate diet are also administered. In a related method Crohn&#39;s disease is screened for by performing an ELISA analysis for serum antibodies to MAP, and, for patients screening positive for MAP, the antibiotic regimen is administered.
This invention proposes an agent to block the &#34;fuel supply&#34; that energizes cancer cell growth by protecting surrounding cells to the cancer, particularly stromal fibroblast cells. The invention disables the products of surrounding cells useable for energy conversion by the cancer cell thereby crippling the cell and disabling its growth process. This application describes the use of a formulation of liposomally encapsulated glutathione that is preferably used orally to increase the level of glutathione in tissues in order to prevent and reverse the metabolic changes in cells that results in the formation of the metabolic fuel that supports cancer cells and to prevent the oxidative stress that damages normal support cells such as fibroblasts and can prevent and reverse these cells from the steps of autophagy and mitophagy that results in the cells decreasing the normal mitochondrial production of ATP for energy and resorting to the use of aerobic glycolysis for energy production. The use of oral liposomally encapsulated glutathione will maintain the presence and normal function of caveolin in fibroblast and other cells, thus preventing their conversion to autophagic tumor stromal cells. By stopping the formation of autophagic cells, the production of the metabolic fuel needed by cancer cells is stopped, which results in the death of the cancer cells. Compositions using liposomally encapsulated glutathione and other compounds that enhance the favorable effects of liposomal glutathione on cancer disease are referenced.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a new peptide that performs high antibacterial effect, cell growth promoting action and bone differentiation inducing action so as to be a substitute for an autologous serum or bovine fetal calf serum and is contained as an active ingredient in a serum-free medium.  &lt;P&gt;SOLUTION: The antimicrobial peptide comprises a specific amino acid sequence. The antifungal agent comprises the peptide. The composition having sterilization and/or growth inhibitory action contains an effective amount of the peptide as an active ingredient. The medical device and apparatus contain the peptide and have antimicrobial property. The method for sterilization and/or growth inhibition of fungi comprises administration of the peptide. The cell growth promoting factor comprises the antimicrobial peptide. The bone differentiation inducing factor comprises the antimicrobial peptide. The serum-free medium comprises the antimicrobial peptide.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
PURPOSE:An agent for decreasing blood viscosity containing a specific compound as an active ingredient. CONSTITUTION:An agent for decreasing blood viscosity containing, as an active ingredient, a compound expressed by formula I (R represents H, methyl or acetyl; X represents H3C-N, formula II-IV, etc.) (example; tetrandrine, fangchinoline, tetrantrine 2&#39;-N-beta-oxide, tetrantrine 2&#39;-N-alpha-oxide, etc.). For obtaining the compound, for example, Stephania tetrandra is extracted with water and/or alcohols and the solvent is removed from an extract to obtain a residue, which is partitioned between water or a mixed solvent of water with alcohols and an organic solvent such as n-hexane, etc., to remove a fat- soluble component transferred to the organic solvent. Then the residue is dissolved in aqueous ammonia of pH 9 and extracted with chloroform to obtain an aqueous ammonia extract and a chloroform extract. Then the latter is subjected to column chromatography using water, etc., as an elution solvent, followed by fractionation with this layer chromatography.
The present invention relates to Pu&#39;er health care tea and a preparation method thereof. The present invention is characterized in that the Pu&#39;er health care tea is prepared from the raw materials of the following weight ratio: 15 to 25 portions of Pu&#39;er tea, 3 to 8 portions of ginseng and 2 to 5 portions of dendrobe; one or two or three of 2 to 5 portions of indian bread, 2 to 5 portions of gynostemma pentaphylla and 3 to 8 portions of longan pulp can also be added into the components. After the Pu&#39;er tea, the ginseng and the dendrobe are compounded according to a specific proportion, the Pu&#39;er health care tea of the present invention has the effects on arousing the spirit, restoring consciousness, generating body fluid, quenching thirst, reducing fat, reducing blood pressure, nourishing the stomach, protecting the stomach, improving eyesight, clearing fire, tranquilizing, nourishing the blood, strengthening yang, benefiting Qi, enhancing resistance, etc. After the indian bread is added into the components, the Pu&#39;er health care tea has the functions of eliminating dampness, promoting urination, benefiting the spleen, nourishing the stomach and promoting digestion. After the gynostemma pentaphylla is added into the components, the Pu&#39;er health care tea enhances the functions of reducing fat and reducing weight. After the longan pulp is added into the components, the Pu&#39;er health care tea improves the mouth feel of the health care tea. The longan pulp contains abundant components, such as glucose, vitamins, etc., and has certain effects on eliminating fatigue and enhancing body resistance; thus, the Pu&#39;er health care tea is especially suitable for patients with hypertension, diabetes and urinary system inflammation to drink.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for culturing a human skin stem cell and/or an epidermal progenitor; and to provide a method for obtaining reconstructed skin.  &lt;P&gt;SOLUTION: The library or cultured product of the human undifferentiated skin stem cell and/or epidermal progenitor is obtained by using an effective amount of a compound selected from an LIF, an LIF analogue, an LIF mimetic, a product capable of stimulating the expression of an endogenous LIF, and a mixture thereof. The reconstructed epidermides and/or the reconstructed skin is also obtained therefrom. The kit for producing the library of the reconstructed epidermides and/or reconstructed skin, and the method for preparing the stem cell or reconstructed epidermides intended for the treatment of individuals exhibiting the damaged skin (e.g. the individuals suffering from third degree burns, and the individuals suffering from genetic disease affecting the skin) are also provided.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PROBLEM TO BE SOLVED: To obtain a preparation for injection, having high clarity and stability, stimulation on macrophage, antitumor action, pyrogenicity, etc., by dissolving a lipid A analog in an alkali aqueous solution and adding a buffer solution to the solution. SOLUTION: A lipid A analog or its pharmacologically permissible salt (e.g. a compound of the formula) is dissolved in an alkali aqueous solution such as 0.001-0.005 M aqueous solution of sodium hydroxide, heated for 10 minutes to 3 hours while heating the solution at 30-60 deg.C and then a buffer solution such as 1-20 mM buffer solution of phosphoric acid is added to the solution and the solution is finally adjusted to pH 4-9. Preferably a saccharide such as lactose is added to the buffer solution. The objective preparation for injection comprises the lipid A analog which is associated and is made into approximately spherical particles having &lt;=30 nm average particle diameter. The associated body can be freeze-dried without being destroyed.
This invention deals with an enhanced medical treatment system which seeks input from the patient and the physician about the medical problems faced by the patient. It analyzes this information and seeks to guide physicians to a correct diagnosis of the complaint. It also seeks to educate the patient about his/her medical problems and provides information about the problem. It is able to store all this information, so that a continues record of the patient&#39;s visits and problems is kept on file and the physician is able to utilize the medical history to solve the patient&#39;s current problems. With this system in place the medical establishment will be able to improve health care delivery to the patients and be able to better manage the process of the providing health care. Furthermore, this system will also lower the cost of providing health care without compromising on the quality of health care.
PROBLEM TO BE SOLVED: To provide a health food article that prevents collagen reduction, eyesight reduction, and blood glucose level rising or the like accompanying aging of a human body; and a production method of the same.SOLUTION: A jelly collagen is heated, liquefied, mixed with purple yam and a powder of mulberry leaves, thereby eyesight reduction by aging can be prevented because it includes a component of the purple yam. Moreover, absorption action of carbohydrates and sugars of the purple yam can be suppressed because it includes a component of the mulberry leaves. Further, flavonoids and dietary fibers included in the mulberry leaves lower cholesterol levels and neutral fat, LDL cholesterol is prevented from being oxidized by active oxygen, and arterial sclerosis is prevented. The γ aminobutyric acid (GABA) included in the mulberry leaves prevents rising of blood pressure. Collagen that reduces with age can be ingested from a component of pig&#39;s trotters. The collagen can be used as liquid dressing and sauce without limiting it to a jelly one.
PCT No. PCT/EP91/01017 Sec. 371 Date Nov. 30, 1992 Sec. 102(e) Date Nov. 30, 1992 PCT Filed Jun. 3, 1991 PCT Pub. No. WO91/18917 PCT Pub. Date Dec. 12, 1991.The invention includes compounds of the following formula   &lt;IMAGE&gt;   where A and B either A and B form an additional double bond and D is a hydrogen atom or B and D form an additional double bond and A is a hydrogen atom and the other variables are as defined in the specification. Also disclosed is a process of making the compounds and a process of using the compounds to make compounds of the following formula   &lt;IMAGE&gt;   where the variables are defined in the specification. These compounds are useful as antigestigens.
&lt;P&gt;PROBLEM TO BE SOLVED: To compose metal colloid only from natural sources.  &lt;P&gt;SOLUTION: A metal ion solution and a pH compensation agent are added to a treatment liquid obtained by adding a surfactant to water, and stirring is performed while the temperature of the treatment liquid is controlled in a reducing atmosphere, thus the metal ions are reduced to produce metal colloid. The produced metal colloid is noble metal colloid in which the metal is gold, silver, the platinum group or the like. As the reducing agent, low molecular weight alcohol is used. As the surfactant, glycerol fatty acid ester is used. As the metal ion solution, a solution of the acids of chlorinated noble metal is used. As the pH compensation agent, sodium hydrogen carbonate is used. The metal colloid is produced at a pH from a neutral region to a weak alkali region. Regarding its oxidation-reduction potential after the completion of the reduction reaction, it is a negative electric charge, and a negative potential higher than (-)200 mV is shown.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PURPOSE:To obtain a bathing agent composition containing a xanthine derivative and excellent in moist feeling of skin and warm feeling of body. CONSTITUTION:This bathing agent composition contain &gt;=0.05wt.%, preferably 0.1-20wt.% of a xanthin derivative isolated by synthesis or from a plant such as tea leaf, etc. As the xanthin derivative, one or two or more kinds of xanthin derivatives selected from a group consisting of aminophylline, theophylline, caffeine are preferably used. The moist feeling of skin and warm feeling of body is further enhanced by combinedly using inorganic salts, (e.g. sodium sulfate), an organic acid (e.g. succinic acid), a carbonic acid salt (e.g. sodium hydrogen carbonate) and an oily ingredient (e.g. glyceride myristate) together with the xanthin derivative. The bathing agent composition is used in an amount so as to provide 0.1-200ppm concentration of the xanthin derivative at a time in bathing.
PURPOSE: A composition containing Pueraria lobata extract for women&#39;s heath of menopause is provided to enhance blood estrogen concentrate and to reduce abdominal obesity. CONSTITUTION: A composition for improving women&#39;s health of menopause contains Pueraria lobata extract as an active ingredient. The extract is isolated using alcohol solvent. The Pueraria lobata extract contains 5-10% of puerarin and 1-3% of diadzin. The composition is used for reducing body fat and blood neutral fat level and suppresses bone density loss and breast cancer risk. The composition is a pharmaceutical composition containing pharmaceutically acceptable carrier, excipient, and diluent and is formation in the form of powders, granules, tablets, capsules, or injections.
NEW MATERIAL:A cyclopentene derivative shown by the formula I (R and R&lt;1&gt; are H, CH3, or C2H5). EXAMPLE:4-(2,2,3-Trimethylcyclopenta-3-en-1-yl)-2-butene-1-ol. USE:Useful as a modifier for imparting durable fragrance and flavor. Having fragrance and flavor like natural sandalwood, showing sweet, mild, and natural fragrance of good body. Useful as a fragrant component for various foods and drinks, cosmetic, health and hygiene, drugs, etc. Miscible well with other synthetic perfume, natural perfume, etc. PREPARATION:For example, 4-(2,2,3-trimethyl-cyclopenta-3-en-1-yl)-2-butenoic acid shown by the formula II is reacted with a reducing agent such as aluminum lithium hydroxide, etc. at about 0-80 deg.C in an organic solvent, to give the example compound in a compound shown by the formula.
The invention provides a vaccine candidate strain SD01 delta meq with marek&#39;s disease virus meq gene editing deletion, construction and application. The SD01 delta meq vaccine strain of the invention has the preservation number of: CGMCC No.45862. The parent strain of the SD01 delta meq vaccine strain is MDV ultra-strong Chinese variant strain SDCW. After passaging the parental strain SDCW in vitro, 925bp sized fragments were deleted on each of the two meq alleles of the viral genome using CRISPR/Cas9 gene editing techniques. Through PCR identification, gene clone sequencing, RT-qPCR analysis, IFA identification and SPF chicken toxicity test, it is confirmed that the SD01 delta meq strain completely loses pathogenicity and tumorigenicity of a host chicken, has no immunosuppression and has good biological safety. Animal immune challenge protection evaluation experiments show that the SD01 delta meq has good immune protection, and the immune protection index of the current domestic MDV epidemic strain reaches 82.4 percent. Therefore, the SD01 delta meq strain constructed by the invention not only can be used as a candidate strain of a novel MD gene deletion vaccine, but also can be used for developing and utilizing a subsequent novel MD gene engineering vaccine.
The invention discloses a miracle drug for curing otitis media. It is made up through marinating serissa serissoides by distilled spirit. The proportion is: serissa serissoides 1-3 shares, distilled spirit 1-6 shares; the distilled spirit can be replaced by medical alcohol. The invention realizes quick-acting, good effect, low cost, hasn&#39;t any toxin side effect, so it is very safe and reliable. The medicine has functions of clearing away heat and detoxicating, diminishing inflammation, sterilization, making sensile. It can be used to cure acute and chronic otitis media, deafness, tinnitus, and the amygdalitis, head or throat tumefaction, deglutition handicap.
An end to end process is disclosed that includes an installation of a prosthetic component, a prosthetic joint, or repair a musculoskeletal system. The pathway of care comprises a pre-operative pathway of care, an intra-operative pathway of care, and a post-operative pathway of care. An application downloaded to a computer drives the process. The application can include integrated PROMS, pain scores, patient Q&amp;A, surveys, a calendar of events (such as physical therapy visits), and contact to surgeon, doctor, or healthcare provider. The pathway of care is an end to end process utilizing wearable devices, implantable devices, sensorized equipment, and sensorized tools to generate measurement data that supports a pre-operative plan, surgery, and post-operative rehabilitation. The application couples to the devices disclosed herein above to engage the patient one or more tasks such that sensors on the devices generate measurement data. The process provides better patient care while allowing the surgeon, doctor, or healthcare provider to handle more patients.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a system which records that the recipient of a package has opened the package and enables the provider of the package to confirm an opening trace.  &lt;P&gt;SOLUTION: When the recipient of the package opens the package, an opening tag 10 attached to the package transmits a tag ID by radio (a step S11). A radio gateway 20 receives the tag ID, and transmits the received tag ID to a server 40 via a network 30 (a step S12). The server 40 extracts a record corresponding to the tag ID, records an opening state as opened, and records an opening date and time in an opening record management table 50 when the tag ID is received. The provider of the package refers to the opening record management table 50 to recognize the opening state.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
The invention discloses a traditional Chinese medicine formula for treatment of &#39;&#39;condyloma&#39;&#39;. The &#39;&#39;condyloma&#39;&#39; is not caused by pathogenic bacteria, and is not a cancer, and has no infectivity. When a patient drinks a lot of distilled spirit and eats a lot of meat, and then he will drinks a lot of tea because of thirst. If the patient keeps doing this for a long time, damp is gathered in spleen and stomach, and is harm for spleen and stomach, and then a heat toxin is formed, and condyloma grows in private parts which are the most delicate and weakness parts -of human body. The medicine comprises 10 portions of artemisia apiacea, 6 portions of ramulus cinnamomi, 3 portions of polyporus, 3 portions of poria cocos, 3 portions of atractylodes and 3 portions of rhizoma alismatis. 500g water and all the ingredients above are added into a crock pot, and boiled for 15min with heavy fire. The medicine is taken when it is still warm. Dosage and administration are that: three times a day, taking two portions of the medicine and then stopping for three days. Great relief will be brought when 5 portions of medicine are taken, and the &#39;&#39;condyloma&#39;&#39; will atrophy and disappear in 15 days.
In various example embodiments, a system and method for facilitating proximity detection and location tracking using a mobile wireless bridge are provided. The system includes a beacon badge, a beacon tag, and a real-time location services (&#34;RTLS&#34;) server communicatively coupled to the beacon badge, such as via a wireless network or the like. The beacon tag broadcasts a beacon message receivable by the beacon badge. The beacon badge determines whether it is proximate to the beacon badge based on the signal strength of the received beacon message. The beacon badge further communicates identifying information contained with the received beacon message to the RTLS server. The RTLS server uses the identifying information to determine the proximate location of the beacon badge.
NEW MATERIAL:A carbostyril derivative shown by the formula I (R1 and R2 are H, or 1-4C lower alkyl; R3 is 1-4C lower alkyl; bond between 3- and 4-positions is single or double bond). EXAMPLE:5-(1-Isobutyryloxy-2-isopropylamino)butyl-8-isobutyryloxycarbo styril. USE:Useful as a drug having bronchodilating action. PREPARATION:A compound shown by the formula II is reacted with a compound shown by the formula III (X is halogen or O; n is 1 when X is halogen atom and 2 when X is O) in a solvent such as preferably dichloromethane, etc. at 0-70 deg.C, to give a compound shown by the formula I . The compound shown by the formula II is a novel compound, and is synthesized by reacting a compound shown by the formula IV with a compound shown by the formula V (X&#39; and X are halogen) to give a compound shown by the formula, reacting this compound with an amine shown by the formula VI, reducing the reaction product with a hydrogenating agent, etc.
PURPOSE:To obtain an external drug for skin, by using an extract of water-soluble blueberry as an active component and adding a sugar alcohol as a stabilizer. CONSTITUTION:Fruit of wild or cultured blueberry is crushed and extracted with water or a water-soluble solvent. The extracted liquid is concentrated and dried to obtain an extract of water-soluble blueberry component as dark reddish purple powder. The objective external drug for skin is produced by using the blueberry component as an active component and adding a sugar alcohol (a polyhydric alcohol produced by reducing carbonyl group of a sugar molecule; e.g. sorbitol, mannitol, maltitol, etc.) as a stabilizer in an amount of &gt;=5wt% based on the whole composition. The stability of the agent can be further improved by acidifying the agent to 3-6 pH with an organic acid (e.g. citric acid, lactic acid, etc.) or its salt or by using an antioxidant such as sodium sulfite, etc. The agent may be used in combination with cosmetics or various other drugs.